bioRxivBiochemistryPreprint
Structural and Functional Comparison of SARS-CoV-2-Spike Receptor Binding Domain Produced in Pichia pastoris and Mammalian Cells
Argentinian AntiCovid Consortium, C. R. Arbeitman, G. Auge, M. Blaustein, L. Bredeston, E. S. Corapi, P. O. Craig, L. A. Cossio, L. Dain, C. D'Alessio, F. Elias, N. B. Fernandez, J. Gasulla, N. Gorojovsky, G. E. Gudesblat, M. G. Herrera, L. I. Ibanez, T. Idrovo, M. Iglesias Rando, L. Kamenetzky, A. D. Nadra, D. G. Noseda, C. H. Pavan, M. F. Pavan, M. F. Pignataro, , A. M. Zelada
Abstract
The yeast Pichia pastoris is a cost-effective and easily scalable system for recombinant protein production. In this work we compared the conformation of the receptor binding domain (RBD) from SARS-CoV-2 Spike protein expressed in P. pastoris and in the well established HEK-293T mammalian cell system. RBD obtained from both yeast and mammalian cells was properly folded, as indicated by UV-absorption, circular dichroism and tryptophan fluorescence. They also had similar stability, as indicated by temperature-induced unfolding (observed Tm were 50 {degrees}C and 52 {degrees}C for RBD produced in P. pastoris and HEK-293T cells, respectively). Moreover, the stability of both variants was similarly reduced when the ionic strength was increased, in agreement with a computational analysis predicting that a set of ionic interactions may stabilize RBD structure. Further characterization by HPLC, size-exclusion chromatography and mass spectrometry revealed a higher heterogeneity of RBD expressed in P. pastoris relative to that produced in HEK-293T cells, which disappeared after enzymatic removal of glycans. The production of RBD in P. pastoris was scaled-up in a bioreactor, with yields above 45 mg/L of 90% pure protein, thus potentially allowing large scale immunizations to produce neutralizing antibodies, as well as the large scale production of serological tests for SARS-CoV-2.
- organism: yeast
- assay: proteomics
- research focus: protein folding & dynamics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The nuts and bolts of SARS-CoV-2 Spike Receptor Binding Domain heterologous expression
M. Maffei, L. C. Montemiglio, … E. Marra·bioRxiv·Sep 17, 2021
- Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine Candidate
Wen‐Hsiang Chen, Jeroen B. K. Pollet, … María Elena Bottazzi·Protein Expression and PurificationPeer-reviewed·Oct 21, 2021
- Production of a Highly Immunogenic Antigen from SARS-CoV-2 by Covalent Coupling of the Receptor Binding Domain of Spike Protein to a Multimeric Carrier
Argentinian AntiCovid Consortium, P. M. Berguer, … A. M. Zelada·bioRxiv·Apr 25, 2021
- Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells
C. Gstoettner, T. Zhang, … E. Dominguez-Vega·bioRxiv·Feb 23, 2021
- SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice
J. Pollet, W.-H. Chen, … M. E. Bottazzi·bioRxiv·Nov 4, 2020
- High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector.
M. V. Sinegubova, N. A. Orlova, … I. I. Vorobiev·bioRxiv·Nov 4, 2020